Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE recommends NHS use of new melanoma drugs

  • Comment

Advanced melanoma sufferers should be given two life-prolonging drugs by the NHS, according to draft guidance from health watchdog NICE.

The drugs, ipilimumab and vemurafenib, are used to treat patients with advanced malignant melanoma, which is classed as the most dangerous of skin cancers.

Those diagnosed with the disease often have just months to live, but NICE is proposing use of the life-extending treatment on the NHS in England and Wales.

The director of NICE’s Health Technology Evaluation Centre, Professor Carole Longson, said new therapies such as these are vital to improve the quality of life of patients, as their prognosis is often very poor.

NICE had originally decided not to recommend use of the two drugs, but has decided to reverse that decision due to their cost-effectiveness, as long as they are discounted by manufacturers Roche and Bristol-Myers Squibb.

Roche’s vemurafenib is used to treat metastatic melanoma. It is also known as zelboraf. Ipilimumab is recommended for people suffering from malignant melanoma following chemotherapy.

Use of the drugs is classed as a “great stride forward” by the chief executive of the London-based Institute of Cancer Research, Professor Alan Ashworth.

“It is a brilliant example of what new-generation targeted cancer therapies can achieve,” he said.

Decisions will be made locally by NHS groups on the use of the two drugs until NICE issues its final guidance.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs